Literature DB >> 30638266

High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells.

A L Rodríguez-Perea1,2, M Rojas3,4, P A Velilla-Hernández1.   

Abstract

Regulatory T cells (Tregs ) modulate the magnitude of immune responses and possess therapeutic potential in an array of immune diseases. Statins reduce the activation and proliferation of conventional T cells (Tcons ), and they seem to up-regulate the frequency and function of Tregs . However, there is a lack of simultaneous evaluation of the in-vitro effect of statins on the functional profile of Tregs versus Tcons . Herein, magnetically purified Tcons and Tregs were stimulated with CD3/CD28/interleukin (IL)-2 in the presence of atorvastatin (ATV) at 1 or 10 µM. The suppressive function of Tregs , the expression of markers associated with Treg function, activation levels, cytokine production and calcium flux in both subpopulations were assessed by flow cytometry. ATV had no cytotoxic effect on T cells at the concentrations used. Interestingly, 10 µM ATV hampered the suppressive capacity of Tregs . Moreover, this higher concentration reduced the expression of forkhead box protein 3 (FoxP3), cytotoxic T lymphocyte antigen (CTLA-4) and programmed death 1 (PD-1). In Tcons , ATV at 10 µM decreased PD-1 and CD45RO expression. The expression of CD25, CD69, CD95, CD38, CD62L, CCR7 and perforin was not affected in both subpopulations or at any ATV concentrations. Remarkably, 10 µM ATV increased the percentage of tumour necrosis factor (TNF)-α-producing Tregs . Although there was a reduction of calcium flux in Tcons and Tregs , it was only significant in 10 µM ATV-treated Tcons . These results suggested that 10 µM ATV affects the cellular functions of both populations; however, this concentration particularly affected several aspects of Treg biology: its suppressive function, cytokine production and expression of Treg -specific markers.
© 2019 British Society for Immunology.

Entities:  

Keywords:  Ca2+ flux; FoxP3; Regulatory T cell; activation; statin

Mesh:

Substances:

Year:  2019        PMID: 30638266      PMCID: PMC6468172          DOI: 10.1111/cei.13260

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Use of statins is associated with an increased risk of rheumatoid arthritis.

Authors:  H J I de Jong; O H Klungel; L van Dijk; R J Vandebriel; H G M Leufkens; J W van der Laan; J W Cohen Tervaert; H van Loveren
Journal:  Ann Rheum Dis       Date:  2011-10-06       Impact factor: 19.103

2.  Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay.

Authors:  Rui Mao; Wei Xiao; Haitao Liu; Bo Chen; Bing Yi; Piotr Kraj; Jin-Xiong She
Journal:  Biochem Pharmacol       Date:  2013-03-26       Impact factor: 5.858

3.  Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.

Authors:  Christian Mottet; Holm H Uhlig; Fiona Powrie
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

4.  Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.

Authors:  Robert L Lins; Katelijne E Matthys; Gert A Verpooten; Patrick C Peeters; Max Dratwa; Jean-Claude Stolear; Norbert H Lameire
Journal:  Nephrol Dial Transplant       Date:  2003-05       Impact factor: 5.992

5.  Atorvastatin interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis.

Authors:  P-T Brinkkoetter; U Gottmann; J Schulte; F J van der Woude; C Braun; B A Yard
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

6.  Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells.

Authors:  Michihisa Jougasaki; Tomoko Ichiki; Yoko Takenoshita; Manabu Setoguchi
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

7.  Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.

Authors:  Xin Zhang; Jianping Jin; Xueyan Peng; Vinod S Ramgolam; Silva Markovic-Plese
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

8.  Statins induce the accumulation of regulatory T cells in atherosclerotic plaque.

Authors:  Xiao Meng; Kai Zhang; Jingjing Li; Mei Dong; Jianmin Yang; Guipeng An; Weidong Qin; Fei Gao; Cheng Zhang; Yun Zhang
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

9.  Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis.

Authors:  Johannes Fessler; Andrea Raicht; Rusmir Husic; Anja Ficjan; Christine Schwarz; Christina Duftner; Wolfgang Schwinger; Winfried B Graninger; Martin H Stradner; Christian Dejaco
Journal:  Front Immunol       Date:  2017-03-20       Impact factor: 7.561

10.  mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function.

Authors:  Hu Zeng; Kai Yang; Caryn Cloer; Geoffrey Neale; Peter Vogel; Hongbo Chi
Journal:  Nature       Date:  2013-06-30       Impact factor: 49.962

View more
  7 in total

Review 1.  Medical Treatment Can Unintentionally Alter the Regulatory T-Cell Compartment in Patients with Widespread Pathophysiologic Conditions.

Authors:  Sabrina N Copsel; Thomas R Malek; Robert B Levy
Journal:  Am J Pathol       Date:  2020-08-01       Impact factor: 4.307

2.  CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.

Authors:  Yurong Gu; Xiangyong Li; Yanhua Bi; Yubao Zheng; Jialiang Wang; Xiaoyan Li; Zexuan Huang; Lubiao Chen; Yanlin Huang; Yuehua Huang
Journal:  Aging (Albany NY)       Date:  2020-01-12       Impact factor: 5.682

3.  Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.

Authors:  Min Wu; Li Jiang
Journal:  Dig Dis Sci       Date:  2021-01-26       Impact factor: 3.199

4.  Role of chemokines in hepatocellular carcinoma (Review).

Authors:  Dongdong Xue; Ya Zheng; Junye Wen; Jingzhao Han; Hongfang Tuo; Yifan Liu; Yanhui Peng
Journal:  Oncol Rep       Date:  2020-12-22       Impact factor: 3.906

5.  DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  Danjun Song; Yining Wang; Kai Zhu; Lingyu Tian; Qiang Gao; Jian Zhou; Jia Fan; Xiaoying Wang
Journal:  World J Surg Oncol       Date:  2020-07-20       Impact factor: 2.754

Review 6.  Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?

Authors:  Yan-Mei Qiu; Chun-Lin Zhang; An-Qi Chen; Hai-Ling Wang; Yi-Fan Zhou; Ya-Nan Li; Bo Hu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

7.  Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6.

Authors:  Jitong Sun; Pritam Kumar Panda; Shailesh Kumar Samal; Rajeev Ahuja; Sofia Ajeganova; Ingiäld Hafström; Anquan Liu; Johan Frostegård
Journal:  ACR Open Rheumatol       Date:  2021-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.